Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Nudelman

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Cancer Research|May 3, 2006
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell deathLonnie P Swift, Ada Rephaeli, Abraham Nudelman, et al.
European Journal of Medicinal Chemistry|December 17, 2010
Structure--activity relationship studies of 1-(4-chloro-2,5-dimethoxyphenyl)-3-(3-propoxypropyl)thiourea, a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type-1Michal Weitman, Keti Lerman, Abraham Nudelman, et al.
Molecular Cancer Therapeutics|July 29, 2003
Sequence specificity of adriamycin-DNA adducts in human tumor cellsSuzanne M Cutts, Lonnie P Swift, Ada Rephaeli, et al.
Journal of Medicinal Chemistry|April 27, 2007
De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variantsAlon Herschhorn, Lena Lerman, Michal Weitman, et al.
Molecular Cancer Therapeutics|February 18, 2003
Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramineLonnie P Swift, Suzanne M Cutts, Ada Rephaeli, et al.
Cancer Letters|July 6, 2007
The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic propertiesDiana Blank-Porat, Tal Gruss-Fischer, Nataly Tarasenko, et al.
Cancer Biology & Therapy|July 25, 2003
Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cellsBelinda S Parker, Suzanne M Cutts, Abraham Nudelman, et al.
Cancer Letters|March 10, 2007
AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell linesMichal Entin-Meer, Ada Rephaeli, Xiaodong Yang, et al.
Oncology Research|May 5, 2009
Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapyMichal Ugarenko, Chee-Kai Chan, Abraham Nudelman, et al.
Biochemical Pharmacology|September 10, 2009
ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adductsMichal Ugarenko, Abraham Nudelman, Ada Rephaeli, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Cancer Research|May 3, 2006
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell deathLonnie P Swift, Ada Rephaeli, Abraham Nudelman, et al.
European Journal of Medicinal Chemistry|December 17, 2010
Structure--activity relationship studies of 1-(4-chloro-2,5-dimethoxyphenyl)-3-(3-propoxypropyl)thiourea, a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type-1Michal Weitman, Keti Lerman, Abraham Nudelman, et al.
Molecular Cancer Therapeutics|July 29, 2003
Sequence specificity of adriamycin-DNA adducts in human tumor cellsSuzanne M Cutts, Lonnie P Swift, Ada Rephaeli, et al.
Journal of Medicinal Chemistry|April 27, 2007
De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variantsAlon Herschhorn, Lena Lerman, Michal Weitman, et al.
Molecular Cancer Therapeutics|February 18, 2003
Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramineLonnie P Swift, Suzanne M Cutts, Ada Rephaeli, et al.
Cancer Letters|July 6, 2007
The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic propertiesDiana Blank-Porat, Tal Gruss-Fischer, Nataly Tarasenko, et al.
Cancer Biology & Therapy|July 25, 2003
Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cellsBelinda S Parker, Suzanne M Cutts, Abraham Nudelman, et al.
Cancer Letters|March 10, 2007
AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell linesMichal Entin-Meer, Ada Rephaeli, Xiaodong Yang, et al.
Oncology Research|May 5, 2009
Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapyMichal Ugarenko, Chee-Kai Chan, Abraham Nudelman, et al.
Biochemical Pharmacology|September 10, 2009
ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adductsMichal Ugarenko, Abraham Nudelman, Ada Rephaeli, et al.
Pageof 7